EBOS Group Limited (EJG) Price & Analysis
EJG Stock Chart & Stats
- Day’s Range
- EUR 9.85 - EUR 9.95
- 52-Week Range
- EUR 8.80 - EUR 14.00
- Previous Close
- EUR 9.55
- Volume
- 0
- Average Volume (3M)
- 6
- Market Cap
- EUR 2.16B
- Enterprise Value
- EUR 6.29B
- Total Cash (Recent Filing)
- EUR 239.29M
- Total Debt (Recent Filing)
- EUR 1.90B
- Price to Earnings (P/E)
- 15.3
- Beta
- 0.28
- Next Earnings
- Feb 23, 2027
- EPS Estimate
- 0.33
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 6.21%
Bulls Say, Bears Say
Bulls Say
Distribution Infrastructure Efficiency
Completion of the major distribution-centre renewal removes a substantial investment burden while improving operating productivity. Further targeted gains at Kemps Creek could support service capacity, cost efficiency and cash generation, strengthening the core distribution platform over coming periods.
Animal Care Growth
Animal Care is expanding faster than the broader group and combines organic branded growth with acquired capabilities in premium and fresh categories. This gives EBOS a meaningful growth avenue and broadens its earnings base beyond traditional healthcare distribution.
Cash Flow And Financial Flexibility
Positive free cash flow, available committed facilities and a debt profile within management's target range provide meaningful financial flexibility. This supports continued investment, dividends and bolt-on acquisitions while retaining capacity to manage operating volatility.
Bears Say
Revenue And Margin Volatility
The sharp FY2026 revenue contraction and substantial gross-margin compression reduce confidence in the consistency of EBOS's earnings profile. Even if some movement reflects unusual factors, weaker reported economics can constrain reinvestment and make future performance more dependent on recovery.
Community Pharmacy Margin Pressure
Persistent competition and pharmacy margin pressure can limit the earnings benefit of revenue growth in an important business area. A structurally low group margin also leaves less buffer against reimbursement, product-tiering or competitive changes affecting pharmacy economics.
New Zealand Contract Roll-off
The scheduled loss of a major New Zealand wholesaling contract creates a defined earnings and redeployment challenge. Although management estimates the impact at about 1% of group EBITDA, replacing volume and efficiently resizing operations may weigh on results and execution.
EBOS Group Limited News
EJG FAQ
What was EBOS Group Limited’s price range in the past 12 months?
What is EBOS Group Limited’s market cap?
When is EBOS Group Limited’s upcoming earnings report date?
How were EBOS Group Limited’s earnings last quarter?
Is EBOS Group Limited overvalued?
Does EBOS Group Limited pay dividends?
What is EBOS Group Limited’s EPS estimate?
How many shares outstanding does EBOS Group Limited have?
What happened to EBOS Group Limited’s price movement after its last earnings report?
Which hedge fund is a major shareholder of EBOS Group Limited?
What is the TipRanks Smart Score and how is it calculated?
Company Description
EBOS Group Limited
EBOS Group Limited engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, and animal care products in Australia, Southeast Asia, and New Zealand. It operates through Healthcare and Animal Care segments. The company provides healthcare logistics; medication management solutions; pharmacy management software; loyalty, generics, compliance, business intelligence, and store software services; and health communications, programs, and consultancy services. It also offers community based health care services and programs; vitamins, minerals and supplements, herbal and fruit teas, and natural toothpastes, as well as functional foods, including molasses and manuka honey; Pharmacy Choice, a five step integrated retail program for independent pharmacies; and healthSAVE, a community pharmacy banner that helps members drive their retail businesses. Further, it offers healthcare distribution, warehousing, clinical trial management, and product registration services; clinical trial logistics; aesthetic healthcare devices, medical-grade cosmeceuticals, and injectables; and surgical devices and medical consumables. Additionally, the company provides pet nutrition, treats, clean-up, and grooming products and accessories; and wholesales veterinary products. The company was formerly known as Early Bros Dental & Surgical Supplies Ltd. and changed its name to EBOS Group Limited in 1986. EBOS Group Limited was incorporated in 1922 and is headquartered in Docklands, Australia.
- Sector
- Healthcare
- Industry
- Medical - Distribution
- CEO
- Adam Luke Hall
- Employees
- 5,364
- Website
- www.ebosgroup.com
- Address
- 737 Bourke Street, Docklands, VIC, 3008, AU
EBOS Group Limited (EJG) Earnings & Revenues
EJG Earnings Call
Earnings Call SentimentPositive
The call communicated solid top‑line growth, completion of a major A$360m infrastructure program that materially reduces future capital needs, meaningful momentum in higher-growth divisions (Animal Care, Medical Technology, Retail Pharmacy Brands) and a disciplined M&A and capital allocation approach. Temporary headwinds were acknowledged — notably FX translation, fuel costs, margin pressure and a known NZ contract roll-off — but management framed these as manageable or transitory and backed guidance that excludes further acquisitions. Balance sheet metrics, free cash flow generation and a maintained dividend were highlighted as strengths. Overall the positives (portfolio re‑positioning, completed investment cycle, strong divisional growth and capital flexibility) outweigh the measurable but contained lowlights.
View all DE:EJG earnings summariesEJG Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 6 | 14 |
| Technical Analysis | 2 | 6 | 2 |
| Moving Averages | 0 | 0 | 12 |